510(k) Report

510(k) · Cleared

Cleared

Mrsa Select - Skin and Soft Tissue Wound Specimens

K100589510(k) TraditionalCleared Oct 29, 2010241-day reviewClass II21 CFR 866.1700

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Bio-Rad · JSO Culture Media, Antimicrobial Susceptibility Test, Excluding Mueller Hinton Agar

Cleared on Oct 29, 2010 as substantially equivalent to K081212 (Bio-Rad, 2008) after a 241-day review. Its family tree reaches back 4 generations to 1986. 2 later devices descend from it.

Decided
Oct 29, 2010
Review
241 days
Class
Class II
Product code
JSO
Recalls
None
Predicates
1

Its longest line of descent runs back 4 generations to K863821 (1986). 2 later devices descend from it, 2 citing it directly.

  1. Root · 4 generations backK863821 Mueller Hinton Agar W/4%Nacl and OxacillinGibco Laboratories Life Technologies, Inc. · 1986 · Recalled
  2. 3 generations backK042812 Bblchromagar MrsaBecton, Dickinson & CO · 2004
  3. 2 generations backK070361 MrsaselectBio-Rad · 2007
  4. 1 generation backK081212 Mrsaselect - Extended IncubationBio-Rad · 2008 · Recalled
  5. This deviceK100589 Mrsa Select - Skin and Soft Tissue Wound SpecimensBio-Rad · 2010
  6. Descendant · cites it directly · 0 of its ownK171061 MRSASelect IIBio-Rad · 2017 · Recalled
  7. Descendant · cites it directly · 0 of its ownK151688 chromID MRSAbioMerieux, Inc. · 2016

Most influential descendants

Showing 2 of 2 · See all
  • K171061MRSASelect IIBio-Rad · 2017 · cites it directly0descendants
  • K151688chromID MRSAbioMerieux, Inc. · 2016 · cites it directly0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−4K863821Mueller Hinton Agar W/4%Nacl and OxacillinGibco Laboratories Life Technologies, Inc.19861
−3K042812Bblchromagar MrsaBecton, Dickinson & CO2004—
−2K070361MrsaselectBio-Rad2007—
−1K081212Mrsaselect - Extended IncubationBio-Rad20081
0 (this device)K100589Mrsa Select - Skin and Soft Tissue Wound SpecimensBio-Rad2010—
+1K171061MRSASelect IIBio-Rad20171
+1K151688chromID MRSAbioMerieux, Inc.2016—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
201610
201710
FIG. 1 — Lineage of K100589, 1986–2017Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in JSO? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

  • Candidate predicates for a device like this, rankedin the report
  • Recall history across each candidate’s familyin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K081212Mrsaselect - Extended Incubation
Summary page 1
…5 Substantially Equivalent Device MRSASelect for skin and soft-tissue wounds is substantially equivalent to Bio-Rad MRSASe/ect - extended incubation (reference 5 10(k) K081212). Products are the same chromogenic media used for the detection of MRSA direct from a specimen swab. Manufacturer: Bio-R…
Bio-Rad20081

Also cleared against K081212: 1 other device →

What descends from it? (2)

2 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K171061MRSASelect IIBio-Rad20170
K151688chromID MRSAbioMerieux, Inc.20160

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 24 years and passes through 3 companies; a new generation was cleared every 2.8 years on median.
  • 2 of the 4 ancestors have a recall of any class.
  • Of its descendants, K171061 (Bio-Rad, 2017) has gone furthest, with 0 descendants of its own.
  • 1 other device also cites its predicate K081212.

How does its category compare?

All JSO devices

JSO Culture Media, Antimicrobial Susceptibility Test, Excluding Mueller Hinton Agar: FDA decisions, review times, recalls and adverse event reports over 20 years. 2010, this device’s year, is highlighted.

FDA decisions per year · JSO

1in 2019

2007: 12008: 22009: 12010: 52011: 22012: 12016: 32017: 22018: 12019: 1
2007high 5 (2010) · low 0 (2013)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · JSO

262in 2016

2010: 326 days median2016: 262 days median
2007high 326 (2010) · low 262 (2016)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · JSO

15in 2022

2007: 22009: 42011: 32017: 22020: 12022: 15
2007high 15 (2022) · low 0 (2008)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · JSO

513in 2025

2008: 12010: 12011: 12013: 12015: 322016: 172017: 432018: 142019: 92020: 72021: 272022: 82023: 122024: 42025: 513
2007high 513 (2025) · low 0 (2007)2025

MAUDE reports naming product code JSO, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20071—20
20082—01
20091—40
2010532601
20112—31
20121—00
20130—01
20140—00
20150—032
20163262017
20172—243
20181—014
20191—09
20200—17
20210—027
20220—158
20230—012
20240—04
20250—0513
20260—0—

What is it indicated for?

MRSASelect is a selective and differential chromogenic medium for the qualitative detection of methicillin resistant Staphylococcus aureus (MRSA) from skin and soft-tissue wound specimens. The MRSASelect is indicated for use in conjunction with other laboratory tests and clinical data available to aid in the identification and diagnosis of MRSA from patients with skin and soft-tissue infections. Concomitant cultures and susceptibility testing are necessary for all skin and soft-tissue wound specimens. MRSASelect is not intended to guide, or monitor treatment for MRSA infection, or provides results of susceptibility to methicillin. Results can be interpreted after 18 to 28 hours incubation.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K100589: Mrsa Select - Skin and Soft Tissue Wound Specimens.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K100589

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026